Clonal Evolution

Chromothripsis

Properties1
tagsgenomic-alterations

4 min read

Chromothripsis

Definition

Chromothripsis (from Greek chromo- for chromosome and thripsis, shattering into pieces) is a catastrophic mutational process in which many clustered structural variants arise in a single event, often affecting one or a few chromosomes. First described by Stephens et al. (2011), it is the genomic signature of a one-off cellular crisis — tens to hundreds of rearrangements concentrated in localized genomic regions — rather than gradual accumulation of structural variants over time.

Pan-Cancer Frequency

The PCAWG Consortium (2020) identified chromothripsis in 587 of 2,583 samples (22.3%), making it a common event across cancer types. Highest frequencies were observed in sarcoma, glioblastoma, lung squamous cell carcinoma, melanoma, and breast adenocarcinoma. Chromothripsis was associated with whole-genome-duplication in most cancer types.

Patterns Across Cancer Types

Chromothripsis manifests in cancer-type-specific patterns (PCAWG Consortium, 2020):

  • Liposarcoma: events often involve multiple chromosomes, with universal MDM2 amplification and co-amplification of TERT in select cases
  • Glioblastoma: focal events on a single chromosome, distant from telomeres, resulting in EGFR and MDM2 amplification with CDKN2A loss
  • Acral melanoma: frequent CCND1 amplification; chromothripsis typically precedes most somatic point mutations
  • Lung squamous cell carcinoma: SOX2 amplification; later event in evolution (many amplified SNVs)
  • Chromophobe RCC: events predominantly on chromosome 5, with breakpoints adjacent to TERT, increasing TERT expression ~80-fold

Evolutionary Timing

Chromothripsis tends to be an early event in tumour evolution. PCAWG Consortium (2020) showed that chromothripsis had greater relative odds of being clonal than subclonal, indicating it typically occurs before the emergence of the most recent common ancestor of the tumour cell population. In acral melanoma, chromothripsis events precede most somatic point mutations, affecting several cancer-associated genes simultaneously.

Enrichment for Drivers

Chromothripsis regions coincided with 3.6% of all identified drivers in PCAWG and approximately 7% of copy-number drivers — significantly enriched beyond the expectation if selection were not acting on these events (PCAWG Consortium, 2020). The majority of coinciding driver events were amplifications (58%), followed by homozygous deletions (34%) and structural variants within genes or promoter regions (8%). TP53 was the most recurrently associated driver (pan-cancer odds ratio = 3.22).

Beneficial Chromothripsis: Somatic Rescue in Non-Malignant Cells

Chromothripsis is not exclusively a cancer mechanism — it can, in rare cases, produce a therapeutically beneficial outcome. McDermott et al. (2015) reported a 59-year-old female (WHIM-09) with WHIM syndrome, an autosomal dominant immunodeficiency caused by a gain-of-function CXCR4^R334X mutation. Chromothripsis on one copy of chromosome 2 deleted 164 genes including the mutant CXCR4 allele in a single hematopoietic stem cell (HSC). The corrected HSC — now hemizygous for wild-type CXCR4 — repopulated the bone marrow without conditioning, restoring normal immune function. The patient has remained healthy for at least 20 years (mcdermott2015-chromothriptic-cure-whim).

This is the hopeful-monster concept realized as therapy rather than pathology. The chromothriptic event was confined to a single chromosome — the remaining ~44 chromosomes were intact — and while most HSCs experiencing such catastrophic events likely died from collateral damage, at least one produced a viable configuration where (a) the mutant CXCR4 was deleted and (b) the collateral rearrangements on chromosome 2 were survivable. That cell then had an enormous selective advantage over WHIM-mutant HSCs and swept through the hematopoietic compartment.

The case reveals that chromothripsis is value-neutral: its consequences depend entirely on which genes are lost or rearranged, and in which cell type the event occurs. Most chromothriptic events are probably cell-lethal. A minority produce cancer-driving configurations. An even smaller minority — exemplified by WHIM-09 — produce therapeutic outcomes. This has implications for the interpretation of chromothripsis in cancer genomes: if a chromothriptic event can be beneficial in one context and oncogenic in another, the same event in a tumor may not always represent a driver of progression.

Significance for Clonal Evolution

Chromothripsis represents a mechanism of punctuated-evolution — a saltatory genotype change that can simultaneously alter multiple cancer genes, producing a large fitness jump in a single event rather than incremental adaptation. Its predominantly early, clonal timing means it can be a founding event in tumour evolution, establishing the genomic landscape upon which subsequent gradual evolution operates. The cancer-type-specific patterns suggest that the selective value of chromothripsis depends on tissue context — the same catastrophic process produces different driver combinations in different tissues.

Graph View

Backlinks